Emergence of Ceftolozane-Tazobactam-Resistant Pseudomonas aeruginosa during Treatment Is Mediated by a Single AmpC Structural Mutation | Zendy

Shawn H. MacVane | Zendy; Ruchi Pandey | Zendy; Lisa L. Steed | Zendy; Barry N. Kreiswirth | Zendy; Liang Chen | Zendy

Open Access

Emergence of Ceftolozane-Tazobactam-Resistant Pseudomonas aeruginosa during Treatment Is Mediated by a Single AmpC Structural Mutation

Author(s) -

Shawn H. MacVane,

Ruchi Pandey,

Lisa L. Steed,

Barry N. Kreiswirth,

Liang Chen

Publication year - 2017

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01183-17

Subject(s) - pseudomonas aeruginosa , cephalosporin , microbiology and biotechnology , tazobactam , biology , antibiotics , bacteria , piperacillin , genetics

Ceftolozane-tazobactam is a cephalosporin-β-lactamase inhibitor combination that exhibits potentin vitro activity againstPseudomonas aeruginosa , including strains that are resistant to other β-lactams. The emergence of ceftolozane-tazobactam resistance among clinical isolates ofP. aeruginosa has rarely been described. Here we characterized ceftolozane-tazobactam-resistantP. aeruginosa strains recovered from a patient who was treated with this agent for 6 weeks for a recurrent wound infection. The results showed that the resistance was mediated by a single AmpC structural mutation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research